OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS

OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS

Show other versions (1)

Early treatment with Pulmozyme (dornase alfa) and its prolonged use in combination with basis therapy results in decrease of exacerbation rate, prolongation of remission of bronchopulmonary process with normal ventilation functions of lungs and gives patients with cystic fibrosis an opportunity to l...

Full description

Bibliographic Details
Main Author: O.I. Simonova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2011-07-01
Series:Voprosy Sovremennoj Pediatrii
Online Access:https://vsp.spr-journal.ru/jour/article/view/659
id doaj-df136041c12749ec8aa2b49e2de3cb8d
record_format Article
spelling doaj-df136041c12749ec8aa2b49e2de3cb8d2021-07-28T21:15:28Zeng"Paediatrician" Publishers LLC Voprosy Sovremennoj Pediatrii1682-55271682-55352011-07-01104659OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICSO.I. Simonova0Scientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowEarly treatment with Pulmozyme (dornase alfa) and its prolonged use in combination with basis therapy results in decrease of exacerbation rate, prolongation of remission of bronchopulmonary process with normal ventilation functions of lungs and gives patients with cystic fibrosis an opportunity to live an active life. The drug is effective as a conservative treatment of chronic sinusitis polyposis; it’s frequent complication of cystic fibrosis. Dornase alfa has 3 clinical effects: strong mucolytic, anti-inflammatory and antibacterial effect. That is the reason for the treatment of other chronic bronchopulmonary diseases with this drug. Efficacy of dornase alpha depends on rough maintenance of the terms of drug use.Key words: children, dornase alfa, cystic fibrosis, chronic bronchopulmonary diseases, chronic rhinosinusitis, nasal polyposis, nebulizer therapy.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (4): 145–152)https://vsp.spr-journal.ru/jour/article/view/659
collection DOAJ
language English
format Article
sources DOAJ
author O.I. Simonova
spellingShingle O.I. Simonova
OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
Voprosy Sovremennoj Pediatrii
author_facet O.I. Simonova
author_sort O.I. Simonova
title OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
title_short OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
title_full OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
title_fullStr OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
title_full_unstemmed OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
title_sort opportunities of dornase alfa in pediatrics
publisher "Paediatrician" Publishers LLC
series Voprosy Sovremennoj Pediatrii
issn 1682-5527
1682-5535
publishDate 2011-07-01
description Early treatment with Pulmozyme (dornase alfa) and its prolonged use in combination with basis therapy results in decrease of exacerbation rate, prolongation of remission of bronchopulmonary process with normal ventilation functions of lungs and gives patients with cystic fibrosis an opportunity to live an active life. The drug is effective as a conservative treatment of chronic sinusitis polyposis; it’s frequent complication of cystic fibrosis. Dornase alfa has 3 clinical effects: strong mucolytic, anti-inflammatory and antibacterial effect. That is the reason for the treatment of other chronic bronchopulmonary diseases with this drug. Efficacy of dornase alpha depends on rough maintenance of the terms of drug use.Key words: children, dornase alfa, cystic fibrosis, chronic bronchopulmonary diseases, chronic rhinosinusitis, nasal polyposis, nebulizer therapy.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (4): 145–152)
url https://vsp.spr-journal.ru/jour/article/view/659
work_keys_str_mv AT oisimonova opportunitiesofdornasealfainpediatrics
_version_ 1721261863034945536

Similar Items